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The genetics of cystic fibrosis lung disease
Donald J Davidson, David J Porteous
Since the isolation of the gene responsible for
cystic fibrosis in 1989 we have witnessed rapid
progress in our understanding of this common
genetic disorder. Progressively more detailed
knowledge of the disease causing mutations,
the gene expression patterns, the protein struc-
ture, and its function as an ion channel has
allowed the development of reliable screening
programmes, the creation of animal models,
and the design of novel therapeutic ap-
proaches. The biological basis of many aspects
of the disease phenotype are becoming clearer,
including recent significant advances in under-
standing the pathogenesis of the characteristic
and ultimately fatal lung disease. While this
great expansion of knowledge has started to
bridge the gap between our understanding of
the genetic defect and the well documented
clinical sequelae, it has also served to demon-
strate the mechanistic complexity of this
“simple” single gene defect.
Cystic fibrosis and the cloning of the gene
Cystic fibrosis is the most common lethal auto-
somal recessive genetic disorder in Caucasian
populations with a carrier frequency of one in
25. It aVects about one in 2500 live births and
has a median life expectancy of 28 years.1
The characteristic manifestations are due
primarily to dysfunction of exocrine glands,
producing viscid, dehydrated secretions. The
resultant phenotype is of salty sweat, pancreatic
insuYciency (with consequent malabsorption
and failure to thrive), intestinal obstruction
(with meconium ileus in 10–20% of patients in
the first few days of life), infertility and severe
pulmonary disease. The electrophysiological
profile of aVected tissues shows characteristic
abnormalities in the transport of chloride and
sodium ions across the apical membrane.2
The recent advancement of our knowledge
was sparked by the cloning, in 1989, of the
gene responsible for the disease—the cystic
fibrosis transmembrane conductance regulator
(CFTR) gene. Located on the long arm of
human chromosome 7, it spans over 250 kb,
contains 27 exons, and encodes a 1480 residue
transmembrane glycoprotein. The protein con-
sists of two repeated motifs made up of six
membrane spanning segments, and a nucle-
otide binding domain (NBD) separated by a
regulatory domain (R domain) with multiple
potential phosphorylation sites. It has been
shown to function as a cAMP regulated
chloride ion channel at the apical membrane of
epithelial cells.3
The clinical problems in cystic fibrosis
reflect the tissue and cell specific expression
pattern of CFTR, being highly expressed in the
epithelial cells of the sweat ducts, the pancre-
atic ducts, the digestive tract, particularly in the
crypts of the small intestine and Brunner’s
glands, the biliary ducts, the salivary glands,
the reproductive organs and the lungs, particu-
larly in the serous cells of the submucosal
glands and in the respiratory epithelial cells.1
Research into cystic fibrosis was further
boosted by the development of transgenic
cystic fibrosis mouse models after the murine
homologue (Cftr) of the human gene was
isolated. The murine CFTR protein is very
similar to the human (78% overall sequence
identity at the amino acid level), particularly in
the two nucleotide binding folds, and the
cAMP dependent chloride ion transport prop-
erties of wild type mice are similar to those of
normal human subjects.4 The first mouse
models of cystic fibrosis were created within
three years of the isolation of the CFTR gene,
using gene targeting in embryonic stem cells to
disrupt the Cftr gene, and to date 10 variants
have been created, all demonstrating the char-
acteristic abnormalities in cAMP mediated
chloride ion conductance, but importantly also
exhibiting a range of clinical phenotypes.5
CFTRmutations
Since the isolation of the CFTR gene there have
been over 600 diVerent mutations identified.6
The most common of these, accounting world-
wide for 68% of the mutant alleles, is ÄF508, a
three base pair deletion in exon 10 that
removes phenylalanine 508 from the first
NBD. Only a handful of others are common
(>1% of the total), but some are significantly
enriched or depleted in specific ethnic popula-
tions. The vast majority are very rare, constitut-
ing a practical challenge to the clinical
geneticist with respect to molecular diagnosis,
but also a valuable epidemiological study
which links protein structure to function and
genotype to phenotype. All classes of mutation
are observed, with the highest density of muta-
tions occurring in the two nucleotide binding
domains.Most known cystic fibrosis mutations
occur in conserved regions suggesting conser-
vation of function across species.
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Mutations in CFTR may result in: (1) defec-
tive CFTR production, such as R553X, due to
unstable mRNA and/or premature protein
truncation, (2) defective processing of CFTR,
such as ÄF508 or G480C, where the mutant
protein is not processed to its mature glyco-
sylated form and is not correctly localised to
the apical membrane, but is retained in the
endoplasmic reticulum and degraded. How-
ever, under permissive conditions in vitro, such
as reduced temperature, correct localisation of
mature protein can occur where it can function
normally (in the case of G480C), or subopti-
mally (in the case of ÄF508), or (3) defective
ion channel function, such as G551D or
R117H, in which case some of the mutant pro-
tein becomes correctly localised but results in
either very little residual function (in the case
of G551D) or a substantially reduced level of
ion transport (in the case of R117H).
In each class of mutation the level of
functional CFTR at the apical membrane of
epithelial cells in patients with cystic fibrosis
falls below a critical level, resulting in the char-
acteristic clinical abnormalities observed in the
organs in which CFTR is expressed.3
The significant advances in our understand-
ing of the disease and the development of new
technologies now allows prenatal diagnosis,
with diagnostic accuracy of 100% in almost all
cases where an aVected family member can be
examined, and the implementation of carrier
screening programmes to help individuals from
aVected families to make informed decisions in
family planning. However, the picture is still
complicated in a significant subset of unusual
cases.
The genotype-phenotype relationship
Understanding the relationship between geno-
type and phenotype is obviously important
from the perspective of prenatal testing, but
also for what it can tell us about the
pathophysiology of the disease and prospects
for intervention.
The mutations in CFTR are usually classi-
fied as either “mild” or “severe” depending
upon whether they confer pancreatic suY-
ciency (PS) or insuYciency (Pl), with one
“mild” allele being enough to result in pancre-
atic suYciency. However, this relatively clear
relationship between genotype and phenotype
does not apply to all the aVected systems.
The common ÄF508 mutation is classified
as “severe”, conferring pancreatic insufficiency
and associated with meconium ileus in ap-
proximately 10% of aVected neonates. The
G551D mutation, although also “severe” and
conferring pancreatic insuYciency, is observed
to be associated with a much lower incidence of
meconium ileus, while the R117H mutation is
a “mild” mutation in which pancreatic suY-
ciency is generally observed. However, all three
mutations are associated with infertility and
lung disease.7
The quantity of normal functional CFTR
can be aVected by alternative splicing of
mRNA such as that associated with the
5-thymidine (5T) variant of the intron 8
polypyrimidine tract (IVS8-T).8 This variant
gives rise to two transcripts—one normal and
one with an in frame deletion of exon 9, the
protein product of which is devoid of cAMP
activated chloride conductance activity. The
level of normal transcript has been shown to be
dependent upon the associated IVS8-T (with
the 5T variant associated with the lowest levels,
increased with the 7T variant and greatest with
the 9T variant), to be tissue dependent, and
consequently to aVect phenotype.9
Asymptomatic individuals homozygous for
the 5T allele and expressing as little as 8% of
normal CFTR in some tissues have been
documented,8 while in other instances these
individuals present with congenital bilateral
absence of the vas deferens (CBAVD). Other
individuals with CBAVD have one recognis-
able CFTRmutation and the 5T variant on the
other chromosome. Furthermore, individuals
carrying the R117H allele are typically more
severely aVected if the R117H mutation is in
cis with the 5T polymorphism as opposed to
the 7T variant, the associated IVS8-T affecting
the amount of already functionally impaired
CFTR that is correctly spliced to influence the
phenotype.7
Thus, detailed studies of the pathophysi-
ological consequences of diVerent mutations
and splicing abnormalities have provided some
insight into the eVects of specific alterations in
the quality or quantity of CFTR and it has
been possible to correlate the level of CFTR
function with phenotype in an organ specific
manner. In this way we can examine the
variable sensitivity of diVerent tissues to CFTR
dysfunction and address the important ques-
tion of how much functional CFTR is required
for therapeutic benefit.
In studies using cystic fibrosis epithelial cell
monolayers the results have suggested that
functional CFTR is only required in approxi-
mately 10% of cells to restore the bioelectric
phenotype to normal.10 Further work with
transgenic cystic fibrosis mice broadly supports
these observation in vivo and demonstrates a
non-linear relationship between gene activity
and intestinal phenotype, the system that is
most severely aVected in the mouse models.11
The specific pathology observed and the
degree of severity varies considerably between
models, resulting in marked diVerences in sur-
vival rates from approximately 10% in the
cftrm1UNC absolute nulls (in which no CFTR is
produced) to approximately 90% in the
cftrm1HGU mice (which produce about 10%
normal CFTR). The results indicate that quite
small corrections in gene activity can have
marked electrophysiological and dramatic
pathological consequences. Together with
clinical observations of diminished disease
severity in the presence of residual function
alleles, the non-linear relationship between
genotype and phenotype underpins the hopes
for successful treatment by gene therapy.
Phenotype modification
While this research is shaping the relationship
between specific mutations, levels of functional
CFTR, and some aspects of phenotype, the
picture is incomplete with further significant
390 Davidson, Porteous
variability being introduced as a result of inde-
pendently segregating modifier genes and vari-
ous environmental factors.
Further insights may come from compari-
sons of the phenotype of individuals with the
same genotype and ethnic background in very
diVerent environments and from studies of
cystic fibrosis twins with age matched siblings
in similar environments and with the same
CFTR genotype.
The cystic fibrosis mouse models will also be
a valuable resource in this regard, not least
because of the ability to control both the envi-
ronment and the genetic cross to compare the
eVect of various Cftr mutations on diVerent
inbred strain backgrounds. In this manner a
locus has already been identified on the proxi-
mal region of mouse chromosome 7 that modi-
fies the onset and severity of intestinal
pathology and survival.12 This region shows
conserved synteny with human chromosome
19q13. It has been suggested that this modifier
could take the form of a calcium dependent
chloride channel that may be able to compen-
sate partially for the absence of CFTR and
alleviate the symptoms.
A significant degree of variability has also
been observed between cftrm1HGU mice on diVer-
ent inbred strain backgrounds with regard to
airway electrophysiology and the response to
inhaled pathogens.13 Studies are underway to
isolate these modifier genes.
The ability of other genes to modify the pro-
gression and severity of cystic fibrosis through
alternative ion channels, the regulation of nor-
mal CFTR production or other mechanisms is
likely to explain some of the variability but it is
probable that environmental influences also
play an important role in humans, particularly
in the development of lung disease.
Other roles for CFTR
Although the primary defect in cystic fibrosis is
in chloride transport, the other classical abnor-
mality observed in cystic fibrosis cells is a
marked increase in the level of sodium absorp-
tion by the amiloride sensitive epithelial
sodium channel (ENaC) across the apical
membrane of the epithelial cells. It has been
shown in vitro that ENaC activity is decreased
in cells overexpressing CFTR, and that cAMP
has an inhibitory eVect on ENaC activity in the
presence of CFTR, but a stimulatory eVect in
its absence.14
CFTR has also been postulated to have a
role in the transport of ATP, either directly as
an ATP channel or as a regulator of ATP trans-
port across both the apical membrane and the
membranes of the intracellular organelles.15
A role in chloride transport has also been
suggested for CFTR across the membranes of
intracellular organelles. In this manner it might
cause a myriad of other eVects by aVecting the
pH balance of the organelles and consequently
the processing of other glycoproteins, altering
the pattern of sulphation and sialylation.16
These secondary functions of CFTR serve to
remind us of the gaps in our knowledge and the
complexities of the physiological processes in
which CFTR is involved.
Lung disease in cystic fibrosis
While the phenotypic analysis described has
provided a considerable amount of information
about disease of the vas deferens, pancreas and
digestive tract, the severity and course of
pulmonary disease are not clearly predicted by
the CFTR genotype.
The precise aetiology of lung disease in
cystic fibrosis is still relatively poorly under-
stood, but is characterised by chronic microbial
colonisation and repeated acute exacerbations
of pulmonary infection, with distinctive bacte-
rial flora precipitating progressive irreversible
inflammatory lung damage. Excessive mucus
production, airway obstruction and atelectasis,
cytokine imbalance and a neutrophil domi-
nated cellular response, producing excessive
amounts of elastase, end in severe bronchiecta-
sis and respiratory failure.
BACTERIOLOGICAL PROFILE OF THE CYSTIC
FIBROSIS LUNG
The environment of the cystic fibrosis lung is
unique and results in characteristic disease
patterns and a specific spectrum of cystic
fibrosis associated lung pathogens. Infants with
cystic fibrosis are typically subject to respira-
tory infections—both with viruses such as res-
piratory syncytial virus (RSV), and bacteria,
such as Staphylococcus aureus and Haemophilus
influenzae, with S aureus predominant in the
first two years of life.17 Aggressive antibiotic
therapy has enabled increased control over
infection with these bacteria that once killed
the majority of cystic fibrosis patients in
infancy.
After the first two years Pseudomonas aerugi-
nosa predominates, with evidence of infection
in the lower airways in a third of cystic fibrosis
infants by the age of five years.18 Early chronic
colonisation with non-mucoid strains may
sometimes be eradicated, but strains tend to
persist in individuals and alter their phenotype.
While there is variability in the time scale for
the emergence of alginate producing mucoid
variants of P aeruginosa, it can occur in as little
as three months after the initial colonisation
and the FEV1, the single best predictor of
mortality, will then decline more quickly in
those patients in whom P aeruginosa has
become mucoid. Despite considerable ad-
vances in the development of anti-
pseudomonal therapy, it remains palliative and
seldom results in eradication of mucoid
strains.17
In the past decade infection with Burkholde-
ria cepacia has become an increasing concern.
Strains of this multi-resistant organism can also
colonise the lungs of patients with cystic fibro-
sis and some strains demonstrate direct cross
infection between patients.17 B cepacia is resist-
ant to a wide range of antibacterial agents,
including cationic peptides,19 and certain
strains are capable of causing rapid clinical
deterioration, fulminating pneumonia, bacter-
aemia, and death.
DEVELOPMENT OF CYSTIC FIBROSIS LUNG DISEASE
The analysis of necropsy material from new-
born infants with cystic fibrosis who die in the
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first few days of life suggests that their lungs are
structurally and functionally normal.20 How-
ever, mild histological abnormalities have been
observed in the respiratory tracts of some cystic
fibrosis infants who died of meconium ileus in
whom there was no evidence of pulmonary
infections,21 and increased levels of IL-8 and
neutrophils have been found in bronchoalveo-
lar lavage fluid from infants with cystic fibrosis
compared with controls, despite negative cul-
tures for the usual cystic fibrosis associated
pathogens.22 This evidence suggests that pul-
monary abnormalities may precede full blown
chronic airways colonisation, but the mecha-
nisms that precipitate these changes remain
uncertain. Whether this represents an exagger-
ated response to minor infectious stimuli that
may themselves have been removed, an inap-
propriately regulated response or, perhaps,
signs of developmental abnormality, it is quite
conceivable that this is the beginning of a
vicious circle of inflammation that will not
properly resolve.
The precise mechanisms by which defective
transepithelial chloride ion transport results in
the observed pulmonary pathology remain
poorly understood. Indeed, it has been sug-
gested that, while CFTR mutations cause
primary lung dysfunction, this alteration to the
lung environment may be a point of no return
after which a self perpetuating process has
begun and subsequent pathology need not
result from a direct interaction with CFTR.
This theory attempts to distinguish between
cystic fibrosis disease, caused and maintained
by CFTR dysfunction, and cystic fibrosis lung
disease, a disease phase triggered by the
former,23 and could, if correct, have significant
bearing on the direction of future research and
the emphasis in the design of novel treatments.
Whether CFTR dysfunction directly results
in the creation of an abnormal lung environ-
ment which harbours infection, or an abnormal
response to cystic fibrosis associated pathogens
produces the characteristic pathology and sub-
sequent clinical sequelae, are questions that
have been diYcult to address. The dissection of
the complex pathogenesis of this disease has
suVered from the limitations imposed by
restricted access to clinical material, a reliance
on necropsy specimens with “end stage” lung
disease, and in vitro techniques. The develop-
ment of mouse models, better in vitro tech-
niques, and a re-evaluation of the old model in
the light of new discoveries has meant that
possible answers to some of the questions are
now being revealed.
LUNG DISEASE IN CYSTIC FIBROSIS MICE
The value of the cystic fibrosis mouse models
in dissecting the pathogenesis of cystic fibrosis
and developing novel treatments derives from
the extent to which they mimic the lung disease
seen in patients with cystic fibrosis. There is no
evidence of pulmonary abnormality at birth in
any of the models and, despite defects in the
electrophysiological profiles of all the mutant
mice, no spontaneous disease has been ob-
served.
In studies of the cftrm1HGU model no lung dis-
ease was observed at birth, nor in animals
raised in isolators. However, histopathological
evidence of pulmonary pathology was noted in
mice reared in normal animal house conditions
in which they are exposed to a low level of
background pathogens. Although no signifi-
cant diVerence existed between the genotypes,
there was a trend towards worse pathology in
the cystic fibrosis mutant mice. Impaired
airway clearance of nebulised S aureus and B
cepacia and the development of significantly
more severe pathogen-specific lung disease
after repeated exposure to these bacteria was
seen in the mutant animals in comparison with
their non-cystic fibrosis littermate controls.24
The spectrum of abnormal pathology included
inflammatory infiltration, goblet cell hyperpla-
sia and metaplasia, mucus retention, bronchi-
olitis, pneumonia and oedema, indicating a
similarity to the histopathology of cystic fibro-
sis lung disease in humans. These studies sug-
gest an increased predisposition to lung disease
in the cystic fibrosis mice when exposed to
specific bacteria, and also that this exposure to
pathogens is crucial to exacerbate the underly-
ing defect.
Further studies on the cftrm1HGU mice have
shown a significant increase in inflammation in
the tracheal lamina propria of cystic fibrosis
mice and significant impairment of mucocili-
ary transport compared with their littermate
controls.25
In recent studies using P aeruginosa in an
agar bead infection model cftrm1UNCmutant mice
have been shown to have significantly higher
mortality rates and raised proinflammatory
cytokines prior to death in comparison with
wild type littermates.26
Thus, the development of transgenic cystic
fibrosis mice has provided the opportunity to
start to investigate disease pathogenesis in vivo,
to interrupt the process at defined stages and
under controlled environmental conditions
(using appropriate controls), to make compari-
sons between diVerent mutations of Cftr, to
search for modifier genes and, as a conse-
quence, to begin to dissect the web of initiating
and potentiating factors downstream of CFTR
that are responsible for the characteristic
pulmonary disease.
It is hoped that within the next couple of
years a sheep model of cystic fibrosis may be
available to supplement the current mouse
studies, providing new opportunities that will
result from a model pulmonary system with
greater anatomical and physiological similari-
ties to man as well as the obvious advantages of
size alone.27
MECHANISMS OF THE PATHOGENESIS OF CYSTIC
FIBROSIS LUNG DISEASE
The traditional model for cystic fibrosis lung
disease involves mucus hypersecretion and
dehydration which upsets normal mucociliary
clearance mechanisms. Bacterial infection and
hyperviscous secretions result in accumulation
of mucus in the airways and airflow obstruction.
Colonisation with cystic fibrosis associated
pathogens occurs and persistent neutrophil
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influx contributes to an excessive and damaging
inflammatory response and cytokine imbalance.
Suppuration leads to ulcerative bronchitis and,
ultimately, bronchiectasis.
Although studies on mucus from patients
with cystic fibrosis suggest a spectrum of rheo-
logical abnormalities,28 mucociliary clearance
studies have been inconclusive29 30 and there is
no evidence to support the hypothesis that the
abnormal function of CFTR, per se, can
induce an impaired mucociliary clearance in
the absence of infection. It is also worth noting
that classical cystic fibrosis lung disease is not
observed in patients with primary ciliary dys-
kinesia syndrome nor in pseudohypoaldo-
steronism. The former is a disorder of
mucociliary clearance that results in rhinitis
and bronchitis and can lead to bronchiectasis,
but generally causes a much less severe lung
disease than cystic fibrosis.31 The latter is a
salt-wasting disorder due to mutations in
subunits of ENaC. The systemic form results
in increased sweat sodium and chloride levels
and chronic excessive secretion from the respi-
ratory tract. However, despite predisposition to
pulmonary infections and asthma like symp-
toms, they seldom develop bronchiectasis.32
Furthermore, neither condition displays the
characteristic bacteriological profile of cystic
fibrosis lung disease.
While evidence continues to show that P
aeruginosa can certainly upregulate mucin
genes,33 new discoveries have reshaped the
original model and started to bridge the gap
between the genetic defect and resultant
pathology in a more satisfactory manner.
The current theories place greater emphasis
upon compromised innate defence mecha-
nisms within the airway surface fluid as a result
of ionic imbalance caused by CFTR dysfunc-
tion and the interaction between epithelial cells
and bacteria.
An innate defence mechanism in the airway
surface fluid
The exciting discovery in 1996 that airway sur-
face fluid had salt sensitive antibacterial
activity34 has precipitated the discovery of an
innate lung defence system comprising a
variety of interacting antimicrobial factors
including naturally occurring antimicrobial
peptides, human â-defensins 1 and 2 (hBD135
and hBD236), lysozyme, and lactoferrin.37
The antibacterial property of airway surface
fluid from primary cultures of normal airway
epithelial cells are observed to be markedly
reduced in the airway surface fluid of cultures
of cells from patients with cystic fibrosis.
Increasing the salt content of normal airway
surface fluid dramatically impairs its antibacte-
rial activity while that of airway surface fluid
from patients with cystic fibrosis can be
restored by lowering its salt concentration,
which suggests that the components of the
defence system are intact but are unable to
function correctly in an environment with high
levels of sodium chloride.34 This led to
speculation that CFTR dysfunction alters the
ionic environment of the cystic fibrosis lung,
impairing the first line of defence against
bacteria and viruses, predisposing these pa-
tients to infection and possibly precipitating a
more pronounced compensatory response
from other components of the defence system,
aVecting neutrophils, macrophages and cyto-
kine production.
This presents an attractive explanation but
attempts to measure accurately the concentra-
tion of sodium and chloride in the airway sur-
face fluid of individuals with and without cystic
fibrosis in vivo have provided conflicting results
and been hampered by sampling diYculties.
Most recent results suggest that the airway sur-
face fluid from patients with cystic fibrosis does
indeed have a higher concentration of sodium
chloride,34 38 perhaps as a result of a failure of
reabsorption similar to that in the sweat
gland,39 but other studies have found no
significant diVerence.40 The development of
techniques to provide accurate measurements
will be crucial for the development of this
hypothesis.
A murine homologue of hBD1 (Defb1) has
now been reported.41 42 Defb1 has been shown
to have a similar expression pattern to hBD1,
including expression in the airways, and
functional studies using a synthetic peptide
have shown a salt sensitive antimicrobial activ-
ity similar in profile to that of its human
counterpart.42 These results suggest that
murine airway surface fluid will be a good
model for the further study of the naturally
occurring peptide antimicrobials and that
compromise of the same innate lung defence
mechanisms in cystic fibrosis mice may be
involved in the abnormal responses observed
when exposed to pathogens.
Epithelial cell interaction
The interaction between bacteria and epithelial
cells encompasses two areas of research—the
adherence of P aeruginosa to asialylated glyco-
proteins on the cell membrane and the
internalisation of P aeruginosa by epithelial
cells.
It has been reported that, in vitro, P
aeruginosa adheres to respiratory epithelial cells
from patients with cystic fibrosis (particularly
ÄF508 homozygotes) significantly better than
to controls43 and with increased aYnity to
damaged and regenerating epithelial cells,44 in
addition, that P aeruginosa pilin (an adhesin
responsible for about 50% of P aeruginosa
binding43) recognise and bind to cell surface
asialoganglioside 1 (aGM1), which is present in
higher levels in cystic fibrosis airway epithelia
than in controls at the expense of the sialylated
protein43 (possibly as a consequence of defec-
tive acidification of intracellular organelles as a
result of CFTR dysfunction).16 The levels of
aGM1 on cystic fibrosis cells are also found to
be further increased in response to P aeruginosa
neuraminidase and are greater on regenerating
cells. Further evidence comes from experi-
ments in which adherence of P aeruginosa is
found to be reduced in primary culture of res-
piratory epithelium from patients with cystic
fibrosis after transfection with human CFTR
gene therapy constructs.45
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These data thus suggest putative pathogen
specific binding sites on airway epithelial cells
with potential for interaction with bacterial
exoproducts, present in greater quantity on
cystic fibrosis cells and after injury. However,
the consequence of these observations and
their in vivo relevance are as yet unclear.
Furthermore, they conflict with post mortem
evidence in which P aeruginosa is observed as
microcolonies in an extracellular mucus layer,
and rarely adherent to cells.46
An alternative avenue of research has
explored the possibility that, as part of the host
defence mechanism, airway epithelial cells may
internalise P aeruginosa, with the lipopolysac-
charide core oligosaccharide acting as the bac-
terial ligand for ingestion.47 It is suggested that
the first extracellular domain of CFTR acts as
a specific cellular receptor. Interestingly, a
deletion from the N-terminal to the fourth
membrane spanning domain has no eVect on
the ion channel properties of CFTR.48
This process of internalisation has been
found, in vitro and in vivo, to be specifically
blocked by appropriate antibodies or peptides
and, in vitro, to be impaired in cystic fibrosis
cells. Preliminary evidence suggests that the
low level of CFTR expression on the apical
surface of airway epithelial cells may be signifi-
cantly upregulated by unknown mechanisms
upon contact with P aeruginosa, form a point of
adherence with the bacteria, and consequently
ingest the organism. It is postulated that expo-
sure to low environmental levels of bacteria,
focal internalisation and cell shedding (perhaps
by a minority of cells ready to be desquamated
in a manner similar to that in corneal infection
with P aeruginosa) might thus clear these
pathogens, a mechanism that would be im-
paired in the absence of apical CFTR or in the
presence of correctly localised but dysfunc-
tional protein.49
However, once again the in vivo relevance of
these observations is uncertain. Initial experi-
ments to study the internalisation in cystic
fibrosis mutant mice have suggested that strain
diVerences may have a more substantial role
than the mutation itself and in an earlier study,
using an identical model of mouse infection,
internalisation was seen mainly in those
animals that developed severe pneumonia and
postulated as a route to more widespread
infection. In addition, it has yet to be shown
that the monoclonal antibodies used in these
studies detect CFTR alone and not a previ-
ously reported cross reacting protein.49
While the two theories of interaction be-
tween epithelial cells and P aeruginosa appear
to be contradictory, the accumulating data
suggest that interaction may play an important
part in the development of lung disease in
cystic fibrosis and, particularly, in conferring
the organism selectivity observed. However,
both hypotheses fail to address the issue of the
mucus barrier that protects the cells from the
luminal contents and the observation that the
disease process originates in the smallest
airways.
The new model (fig 1) now proposes that the
CFTR dysfunction directly aVects the ionic
composition of the airway surface fluid and
compromises the antimicrobial activity of the
salt sensitive first line of lung defence. This
breached, the organisms have a better chance
of colonising the lung. A compensatory re-
sponse from other elements of the defence
mechanism may occur, with an increased neu-
trophil influx, the release of damaging elastase,
cytokine imbalance and the triggering of in-
flammatory cascades, while cell-bacteria inter-
actions may select for specific organisms. The
continuing presence of these organisms may
then further upregulate the expression of
mucin producing genes.
This, of course, is only half of the equation in
which the abnormal environment must in some
way stimulate phenotype alterations in the bac-
teria, with P aeruginosa undergoing mucoid
Figure 1 EVects and influences of CFTR in airway epithelial cells.
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change, thus enhancing its survival and again
interacting with its host to further alter its
environment.
The model goes some way to explain the
pathogenesis of cystic fibrosis lung disease, but
remains incomplete. Development of animal
models in which components of the innate lung
defence system are knocked out are eagerly
awaited. To what extent the absence of this
mechanism in isolation mimics cystic fibrosis
lung disease will help to test the new model, as
will the development of salt insensitive de-
fensins for possible therapeutic use and in vivo
studies examining the interaction between epi-
thelial cells and bacteria.
The model fails to address the role of the
submucosal glands, but with high levels of
CFTR expression in the serous cells and as a
major source of fluid and mucin in the lungs it
seems possible that they may have a role to play
in the maintenance of the ionic composition of
the airway surface fluid. A recent study in the
cftrm1HGU mouse suggests that submucosal
glands may indeed have a role in the develop-
ment of lung disease and highlights this as an
area worthy of further study.50
The current hypothesis also oVers no expla-
nation for the susceptibility to pulmonary
colonisation with B cepacia, which has been
found to be resistant to cationic peptides and
specifically to killing by synthetic hBD1.
42 This
observation suggests that the impairment of
some component of lung defence other than
the antimicrobial properties of airway surface
fluid may be responsible. Pulmonary infection
with B cepacia is very rare other than in cystic
fibrosis, but does occur in chronic granuloma-
tous disease (CGD). This is a condition in
which there is failure of oxidative killing by the
phagocytic cells as a result of an inability to
produce a respiratory burst51 and is character-
ised by recurrent infections, suppurative granu-
lomas, and infiltration of the viscera with
pigmented lipid-laden macrophages. It remains
to be seen whether dysfunctional CFTR can
also cause a defect in oxidative killing.
Treatment
As our understanding of the molecular and
biological basis of cystic fibrosis becomes more
comprehensive, so the ultimate goal of success-
ful treatments becomes more accessible. With
every new insight into the complexity of the
pathogenesis comes a better appreciation of
both the limitations of current treatments and
of new opportunities for therapeutic interven-
tion (table 1). While it is beyond the scope of
this review to detail the current treatment
regimes and trials of novel therapies in
progress, it is worth considering a few impor-
tant issues.
Treatment must aim to improve quality of
life and, if possible, to provide a cure rather
than simply to alleviate symptoms partially.
There is a continuing need and justification for
the development of new antimicrobial agents,
mucolytics, and antiproteases. More directly
relevant to the new genetic knowledge is the
scope for (a) relocating CFTR to the apical
surface, (b) upregulating the function of
correctly localised mutant CFTR, (c) over-
coming stop mutations at the protein transla-
tional level, or (d) compensatory regulation of
alternative ion channels.52 53 Not surprisingly
and, again, appropriately, considerable eVort is
also being invested in gene therapy to replace
the faulty gene directly and thus to correct all
the downstream consequences that arise from
CFTR dysfunction at once.
Gene therapy for cystic fibrosis has been the
victim of initial overenthusiasm in some
quarters, perhaps due to the apparent simplic-
ity of the concept. Adenovirus, adeno-
associated virus, and cationic liposomes have
each been tested in phase I clinical research
studies for transfer of the CFTR gene to respi-
ratory epithelium.54 When proper account is
taken of the highly experimental nature and
early stage of this research, the results, in terms
of both safety and eYcacy, have been reason-
ably encouraging. The hurdles which still need
to be overcome are, however, clear for all to see
(table 2) and this has given rise to an air of dis-
appointment and scepticism by some commen-
tators. Although many issues need to be
addressed in its continuing development, gene
therapy remains an exciting prospect for the
future.
Table 1 Lung disease in cystic fibrosis
Problems Solutions Treatments
Mutation of CFTR Provide normal gene Gene therapy
Overcome stop mutations Aminoglycosides
Abnormal processing of CFTR Relocalisation Molecular chaperones
Defective CFTR Upregulate function Pharmacological agents
Abnormal ion transport Increase chloride transport UTP/ATP
Block sodium uptake Amiloride
Thick obstructive mucus Decrease viscosity Mucolytics
DNAse
Impaired clearance Augment clearance Chest physiotherapy
Pulmonary infection Decrease bacterial load Antibiotics
Salt-insensitive antimicrobial peptides
Pulmonary inflammation Diminish host reaction Antiprotease
Bronchiectasis Replace when irreversible damage Lung transplant
Table 2 Gene therapy for cystic fibrosis
Problems Solutions
IneYcient gene delivery Improved vectors and delivery devices
Inflammatory response to vector Engineering and formulation of viral vectors and liposomes
Lack of cell specific targeting Viral subtypes
Receptor mediated cell targeting
Transient expression Episomal maintenance
Safe site integration
Transfect stem cells
Non-physiological expression Genomic context vectors
Cell specific expression
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The tasks ahead include developing im-
proved vectors and eYcient delivery systems
while avoiding adverse responses, discovering
and targeting the correct cells, and achieving
appropriate levels of expression in these cells
over a lifetime. To this end the further develop-
ment of animal models and continuing basic
research into the cellular andmolecular biology
of this disease is crucial to achieve both
enhanced gene delivery and expression and
improved measurements of surrogate markers
of clinical relevance.
Conclusions
Improvements over the last 25 years in the
symptomatic treatment of cystic fibrosis lung
disease have dramatically improved survival, but
significant further improvements will require
rational approaches based upon a more compre-
hensive understanding of the underlying disease
pathogenesis. In this regard, the molecular clon-
ing of the cystic fibrosis gene was a watershed
and has precipitated dramatic changes in our
perception of the disease. Nevertheless, it takes
time and considerable basic research to translate
gene discovery into new medicines and much
remains to be understood about the intricacies
of CFTR function and the sequelae of dysfunc-
tion. This new knowledge has, however, sug-
gested a variety of radical and revolutionary
approaches worthy of clinical investigation. The
competition and collaboration between the vari-
ous disciplines (microbiology, pharmacology
and molecular biology) will ensure that these
proposals and research findings are critically
reviewed and refined, all to the benefit of the
patient with cystic fibrosis and respiratory medi-
cine in general.
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